Literature DB >> 30765439

Visceral leishmaniasis with haemophagocytic lymphohistiocytosis.

John Titus George1, Mohammad Sadiq1, Elanthenral Sigamani2, Alice Joan Mathuram1.   

Abstract

A 27-year-old man presented with high-grade intermittent fever for 4 months, generalised fatigue for 2 months, intermittent gum bleeds for 1 month and loss of weight of 15 kg. He appeared cachectic with generalised wasting, had pallor and features of reticuloendothelial system proliferation. His liver span was 17 cm. He had massive splenomegaly. His cardiovascular, respiratory and neurological examination were normal. He was diagnosed to have visceral leishmaniasis (VL) based on bone marrow (BM) examination that showed Leishmania donovani (LD) bodies and was treated with liposomal amphotericin (LA). During the course of therapy, he developed bleeding from various mucosal and venepuncture sites. His further evaluation, which included a repeat BM aspirate, showed haemophagocytes. Final diagnosis made was VL with secondary haemophagocytic lymphohistiocytosis. He was continued on LA with intravenous hydrocortisone. He developed refractory distributive shock with multiorgan dysfunction and succumbed to his illness. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  immunology; medical management; tropical medicine (infectious disease)

Mesh:

Substances:

Year:  2019        PMID: 30765439      PMCID: PMC6381973          DOI: 10.1136/bcr-2018-226361

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  23 in total

Review 1.  Natural killer cell dysfunction: A common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis?

Authors:  Alexei A Grom
Journal:  Arthritis Rheum       Date:  2004-03

2.  HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.

Authors:  Jan-Inge Henter; Annacarin Horne; Maurizio Aricó; R Maarten Egeler; Alexandra H Filipovich; Shinsaku Imashuku; Stephan Ladisch; Ken McClain; David Webb; Jacek Winiarski; Gritta Janka
Journal:  Pediatr Blood Cancer       Date:  2007-02       Impact factor: 3.167

Review 3.  Hemophagocytic lymphohistiocytosis in adults: diagnosis and treatment.

Authors:  Claire Larroche
Journal:  Joint Bone Spine       Date:  2012-03-29       Impact factor: 4.929

4.  Herpes simplex virus type 1 renders infected cells resistant to cytotoxic T-lymphocyte-induced apoptosis.

Authors:  K R Jerome; J F Tait; D M Koelle; L Corey
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

Review 5.  Adult haemophagocytic syndrome.

Authors:  Manuel Ramos-Casals; Pilar Brito-Zerón; Armando López-Guillermo; Munther A Khamashta; Xavier Bosch
Journal:  Lancet       Date:  2013-11-27       Impact factor: 79.321

Review 6.  Mechanisms and consequences of persistence of intracellular pathogens: leishmaniasis as an example.

Authors:  Christian Bogdan
Journal:  Cell Microbiol       Date:  2008-03-17       Impact factor: 3.715

Review 7.  Visceral leishmaniasis associated hemophagocytic lymphohistiocytosis--case report and systematic review.

Authors:  Srinivas Rajagopala; Usha Dutta; K S Poorna Chandra; Prateek Bhatia; Neelam Varma; Rakesh Kochhar
Journal:  J Infect       Date:  2008-04-10       Impact factor: 6.072

8.  The unique aspects of presentation and diagnosis of hemophagocytic lymphohistiocytosis in adults.

Authors:  Sarah Nikiforow; Nancy Berliner
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2015

9.  Visceral leishmaniasis-associated mortality in Bangladesh: a retrospective cross-sectional study.

Authors:  M Mamun Huda; Rajib Chowdhury; Debashis Ghosh; Aditya Prasad Dash; Sujit Kumar Bhattacharya; Dinesh Mondal
Journal:  BMJ Open       Date:  2014-07-22       Impact factor: 2.692

10.  Clinical features and prognostic factors of adult secondary hemophagocytic syndrome: Analysis of 47 cases.

Authors:  Yiqun Guo; Yu Bai; Li Gu
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.